Tomografía por emisión de positrones (PET/TC): Presente y futuro de una nueva técnica de imagen en oncología

Cirugia Espanola

Volumn 77, Issue 3, 2005, Pages 111-113

  Gámez, Cristina ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTER ASSISTED TOMOGRAPHY; EDITORIAL; FORECASTING; HUMAN; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY;

FORECASTING; HUMANS; MEDICAL ONCOLOGY; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33644853179     PISSN: 0009739X     EISSN: 1578147X     Source Type: Journal    
DOI: 10.1016/S0009-739X(05)70820-4     Document Type: Editorial

References (28)

1. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol. 1979;6:371-88.
2. Reivich M, Kuhl D, Wolf A, Greenberg J, Phelps M, Ido T, et al. The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res. 1979;44:127-37.
3. Beany RP. Positron emission tomography in the study of human tumors. Sem Nucl Med. 1984;14:324-41.
4. Warburg O, Wind F, Neglers E. On the metabolism of tumors in the body. En:Warburg O, editor. Metabolism of tumors. London: Constable; 1930. p. 254-70.
5. Hatanaka M. Transport of sugars in tumor cell membranes. Biochim Biophys Acta. 1974;355:77-104.
6. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science. 1987;235:1492-5.
7. Monakhov NK, Neistadt EL, Shavlovskil MM, Shvartsman AL, Neifakh SA. Physicochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues. J Natl Cancer Inst. 1978;61:27-34.
8. Wahl RL. Clinical oncology update: the emerging role of PET: part I. En: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Vol. 11(1). Philadelphia: Lippincott-Raven; 1997. p. 1-18.
9. Wahl RL. Clinical oncology update: the emerging role of PET: part II. En: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Vol 11 (2). Philadelphia: Lippincott-Raven; 1997. p. 1-24.
10. Berger KL, Nicholson SA, Dehdashti F, Siegel BA. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR. 2000;174:1005-8.
11. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer: a PET study. J Nucl Med. 1993;34:1-6.
12. Wahl RL. Positron emission tomography: aplication in oncology. En: Murray ICP, Ell PJ, editors. Nuclear medicine in clinical diagnosis and treatment. London: Churchill Livingstone; 1995. p. 801-20.
13. Rigo P, Paulus P, Kascheten BJ, Hustinx R, Bury T, Jerusalem G, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med. 1996;23:1641-74.
14. Medicare coverage policy decisions memorandum [web en línea [citado Jun 2001]. Jun. Disponible en: http://www.hcfa.gov/coverage 8b3-hh2.htm
15. Agencia de Evaluación de Tecnologías Sanitarias (AETS). Instituto de Salud Carlos III. Ministerio de Sanidad y Consumo. Tomografía por emisión de positrones (PET) con 18FDG en oncología clínica (revisión sistemática). Madrid: AETS Instituto de Salud Carlos III; 2001.
16. Protocolo de uso tutelado para la recogida de información sobre la utilización de 18FDG-PET (tomografía por emisión de positrones con 18F-fluordesoxiglucosa). Agencia de Evaluación de Tecnologías Sanitarias (AETS). Madrid: Instituto de Salud Carlos III. Ministerio de Sanidad y Consumo; 2002.
17. Delbeke D, Vitola JV, Sandler MP, Arildsen RC, Powers TA, Wright JK Jr, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med. 1997;38:1196-201.
18. Flamen P, Hoekstra OS, Homans F, Van Cutsem E, Maes A, Stroobants S, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer. 2001;37:862-9.
19. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240:438-47.
20. Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Costeffectiveness of PET imaging in clinical oncology. Nucl Med Biol. 1996:23:737-43.
21. Miles KA. An approach to demonstrating cost-effectiveness of diagnostic imaging modalities in Australia illustrated by positron emission tomography. Australas Radiol. 2001;45:9-18.
22. Zubeldia J, Bednarczyk E, Nabi H. Positron emission tomography in the presurgical evaluation of patients with resectable liver metastases from colorectal carcinoma detected by computed tomography with arterial portography. A Cost Analysis. Clin Positron Imaging. 2000;3:164.
23. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000;41:1369-79.
24. Goerres GW, Von Schulthess GK, Steinert HC. Why most PET of lung and head-and-neck cancer will be PET/CT. J Nucl Med. 2004;45 SUPPL 1:S66-71.
25. Schoder H, Larson SM, Yeung HW. PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med. 2004;45 Suppl 1:S72-81.
26. Wahl RL. Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT. J Nucl Med. 2004;45 SUPPL 1:S82-95.
27. Antoch G, Vogt FM, Freudenberg LS, Nazaradeh F, Goehde SC, Barkhausen J, et al. Whole-body dual-modality PET/CT and wholebody MRI for tumor staging in oncology. JAMA. 2003;290:3248-9.
28. Townsend DW, Carney JP, Yap JT, Hall NC. PET/CT today and tomorrow. J Nucl Med. 2004;45 SUPPL 1:S4-14.